Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
BIOLOGICAL: Epcoritamab
DRUG: Ibrutinib
PROCEDURE: Positron Emission Tomography

Sponsor

Yazeed Sawalha

Collaborators

[object Object]
[object Object]